Abstract P6-11-16: PYTHIA: A phase II study of palbociclib plus fulvestrant versus placebo plus fulvestrant for pretreated patients with ER+/HER2- metastatic breast cancer

MLA

P Flamen, et al. “Abstract P6-11-16: PYTHIA: A Phase II Study of Palbociclib plus Fulvestrant versus Placebo plus Fulvestrant for Pretreated Patients with ER+/HER2- Metastatic Breast Cancer.” Cancer Research, vol. 77, Feb. 2017, pp. P6-11. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi...........60789ecb340ace212a43f83120fe0e85&authtype=sso&custid=ns315887.

APA

P Flamen, Theodora Goulioti, Meredith M. Regan, Dimitrios Zardavas, Barbara Ruepp, A. Hiltbrunner, Luca Malorni, L. Blacher, M.J. Piccart, Rudolf Maibach, & R. D. Gelber. (2017). Abstract P6-11-16: PYTHIA: A phase II study of palbociclib plus fulvestrant versus placebo plus fulvestrant for pretreated patients with ER+/HER2- metastatic breast cancer. Cancer Research, 77, P6-11.

Chicago

P Flamen, Theodora Goulioti, Meredith M. Regan, Dimitrios Zardavas, Barbara Ruepp, A. Hiltbrunner, Luca Malorni, et al. 2017. “Abstract P6-11-16: PYTHIA: A Phase II Study of Palbociclib plus Fulvestrant versus Placebo plus Fulvestrant for Pretreated Patients with ER+/HER2- Metastatic Breast Cancer.” Cancer Research 77 (February): P6-11. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi...........60789ecb340ace212a43f83120fe0e85&authtype=sso&custid=ns315887.